Brief: Septerna-Phase 1 Clinical Trial Ongoing For SEP-786, Oral Small Molecule For Hypoparathyroidism, With Data Expected In Mid-2025
20/11/2024 22:25
Nov 20 (Reuters) - Septerna Inc SEPN.O :
* SEPTERNA-PHASE 1 CLINICAL TRIAL ONGOING FOR SEP-786, ORAL
SMALL
MOLECULE FOR HYPOPARATHYROIDISM, WITH DATA EXPECTED IN MID-2025
Source text: [https://tinyurl.com/muktukk8]
Further company coverage: SEPN.O
Recent news on Septerna
See all newsBrief: Septerna Announces Inducement Grant Under Nasdaq Listing Rule
U.S. RESEARCH ROUNDUP-Cogent Communications, Dollar Tree, Home Depot
Septerna, Inc. reports results for the quarter ended June 30 - Earnings Summary
Septerna Q2 revenue beats analyst estimates, driven by Novo Nordisk partnership
Septerna Q1 revenue rises sharply helped by Novo Nordisk collaboration